Re-assessment of the Actual Benefit of all systemically administered
-
Clinical Benefit
Substantial
Microcrystalline arthritis The actual benefit of FLECTOR in this indication remains substantial.
Osteoarthritis The actual benefit of FLECTOR in this indication remains substantial.
Radicular pain The actual benefit of FLECTOR in this indication remains substantial.
Moderate
Extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis and bursitis The actual benefit of FLECTOR in these indications remains moderate.
Lumbar pain The actual benefit of FLECTOR in this indication remains moderate.
Insufficient
Extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis and bursitis The actual benefit of FLECTOR in these indications remains insufficient in the subpopulation of patients who have risk factors for cardiovascular events.
Lumbar pain The actual benefit of FLECTOR in this indication remains insufficient in the subpopulation of patients who have risk factors for cardiovascular events.
Microcrystalline arthritis The actual benefit of FLECTOR in this indication remains insufficient in the subpopulation of patients who have risk factors for cardiovascular events.
Osteoarthritis The actual benefit of FLECTOR in this indication remains insufficient in the subpopulation of patients who have risk factors for cardiovascular events.
Radicular pain The actual benefit of FLECTOR in this indication remains insufficient in the subpopulation of patients who have risk factors for cardiovascular events.
Listen
